Wednesday, April 22, 2026
35 C
Bengaluru

Generics Only

[wpfilebase tag=file id=90 tpl=download-button /]

Inside this Issue

1. GUEST EDITORIAL: Generics Only – Does the Patient Benefit? by K. Hariram
How much will patients benefit from a regulation that only allows Doctors to prescribe generics?

2. Dinesh Thakur Tackles the Branded v. Generics Debate by Dinesh Thakur
This article features excerpts of a series of blogs written by well-know healthcare entrepreneur, activist and commentator, Dinesh Thakur, on the recent branded v. generics debate.

3. Quality, Not Price, is the Key Issue When Prescribing Generic Drugs in India by Anup Soans
In the absence of a standard drug regulatory mechanism, Indian doctors rely on the reputation of companies who have demonstrated their commitment to quality over time.

Hot this week

Precision Farming Market to Witness Promising Growth Opportunities by 2024-2035

Driven by the ongoing efforts to overcome the inefficiencies...

The Semaglutide Paradox: Anatomy of a High-Stakes Commodity Trap

The Semaglutide Shift: From Blockbuster to Commodity Why the $50...

Cytotoxics to Cell Therapy: A 40-Year Review of Indian Oncology Strategy

In 1989, oncology in India was not a business...

Ritesh Desai has joined Standard Chartered India as Executive Director

Ritesh Desai has joined Standard Chartered India as Executive...

The Healthium Odyssey: From Sutures to Scalpel-Sharp Innovation

The story of Healthium is not just one of...

Topics

Precision Farming Market to Witness Promising Growth Opportunities by 2024-2035

Driven by the ongoing efforts to overcome the inefficiencies...

The Semaglutide Paradox: Anatomy of a High-Stakes Commodity Trap

The Semaglutide Shift: From Blockbuster to Commodity Why the $50...

Ritesh Desai has joined Standard Chartered India as Executive Director

Ritesh Desai has joined Standard Chartered India as Executive...

A Tale of Two Companies – Sun Pharma’s Odyssey and Organon’s Second Act

Sun Pharma’s Odyssey and Organon’s Second Act – And...

The Semaglutide Gold Rush: Miracle Cure or Market Mirage?

The Indian Pharmaceutical Market (IPM) has entered a definitive...
spot_img

Related Articles

spot_imgspot_img